Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation.

Probably not a substantial claim: may not pass S3 (load-bearing).

The AUA panel recommends that clinicians evaluate and treat PD only if they have the experience and tools for proper diagnostic and therapeutic care.

“Based on expert opinion, the AUA guideline panel recommends that clinicians should evaluate and treat PD only if they possess the experience and tools to provide appropriate diagnostic and therapeutic care.1”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourceSupported

Classified as probably not a substantial claim. May combine two claims.

AUA and ISSM recommend ICI but suggest home photography may be sufficient in some cases.

“The AUA and ISSM guideline panels recommend ICI, but hedge by suggesting that home photography may be “sufficient” in some cases.1, 28”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The Diagnosis guideline statement (page unavailable) recommends an in-office ICI test before invasive intervention. Our copy does not suggest that home photography may be sufficient in some cases; searches for home photographs and sufficiency found no such passage. This AUA guideline also cannot establish what the separately cited ISSM panel recommends. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

A careful history and physical examination is required and may be enough for diagnosis, according to expert opinion from AUA, CUA, and ISSM.

“A careful history and physical examination is mandated and may be all that is needed to make the diagnosis based on expert opinion from the AUA, CUA, and ISSM panels.1, 26, 28”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourceSupported
• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourceSupported
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

The AUA panel says no further treatment is needed if the patient chooses observation or non-invasive treatment.

“According to the AUA guideline panel, no further treatment is warranted if the patient selects observation or non-invasive treatments.1”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The Guideline Statements > Treatment section says that, for some patients, counseling may be sufficient and they may choose not to pursue further treatment. It does not say that no further treatment is warranted whenever a patient chooses observation or non-invasive treatment; the claim broadens a qualified statement about patient choice. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The CUA recommends penile traction therapy but emphasizes lack of defined protocols including device type and duration of use.

“The CUA also recommends PTT but emphasizes the lack of defined treatment protocols including type of device and duration of use.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourceSupported

Classified as probably not a substantial claim.

The AUA, CUA, and EAU recommend NSAIDs as first-line therapy for pain in the acute phase of Peyronie's disease.

“AUA, CUA, and EAU panels recommend NSAIDs as first line therapy for pain in the acute phase”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The AUA guideline’s Treatment section says clinicians may offer oral NSAIDs for pain in active Peyronie’s disease. It does not call them first-line therapy or establish what the CUA and EAU panels recommend. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Clinical principle section says oral NSAIDs may be used to control pain during the active phase of Peyronie’s disease. It does not call them first-line therapy or establish that the AUA and EAU panels make the same recommendation. No page number is available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The CUA and EAU panels discuss PDE5 inhibitors such as tadalafil to optimize concurrent erectile dysfunction in men with Peyronie's disease.

“CUA and EAU panels also discuss the potential role for phosphodiesterase-5 inhibitors (PDE5-I) such as tadalafil to optimize concurrent ED”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Clinical principle section says that oral PDE5 inhibitors are used to treat erectile dysfunction concomitant with Peyronie’s disease. It mentions tadalafil specifically for possible effects on plaque progression, not specifically for optimizing erectile dysfunction. The copy cites an EAU guideline but does not establish what the EAU panel says about PDE5 inhibitors for concurrent erectile dysfunction; page numbers are unavailable. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

CUA, EAU, and ISSM discourage MRI, CT, and plain-film X-ray because they lack proven efficacy and involve expense and radiation.

“Other imaging modalities including MRI, CT, and plain-film XRAY are discouraged by the CUA, EAU, and ISSM guideline panels given their lack of proven efficacy, expense, and radiation exposure.26, 28”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  In §4, Investigations (page unavailable), the CUA guideline does not support routine MRI use and says CT and plain radiography have no role in routine Peyronie’s disease evaluation. It does not attribute those positions to expense or radiation exposure, or state the EAU and ISSM panels’ positions. It also calls MRI an excellent imaging modality, rather than saying it lacks proven efficacy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

The AUA states intralesional verapamil may be offered, but supporting evidence is contradictory and weak with unclear balance of benefits and risks or burdens.

“The AUA guideline states that intralesional verapamil may be offered to patients, but emphasizes that the supporting evidence is somewhat contradictory and overall weak with an unclear overall balance between benefits and risks/burdens.”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourceSupported

• AssumptionRests on an assumption: Intralesional verapamil side effects are generally mild and short-lived, and the treatment tends to be well tolerated.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The AUA suggests mechanical therapies including penile traction therapy and vacuum erection devices are possibly promising but require further replication.

“The AUA guideline panel suggests that mechanical therapies including PTT and VED are “possibly promising”, but further replication of the available study data is required.”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The OTHER TREATMENTS section (page unavailable) says that treatments in its table are unproven until a larger or more rigorous evidence base is available, supporting the general need for further study. The passages available from our copy do not identify penile traction therapy or vacuum erection devices as “possibly promising,” or specifically call for replication of their study data. The Treatment section mentions vacuum devices in a different context—as therapy for erectile dysfunction. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

Penile biothesiometry is a non-invasive test for objective sensory information, but its usefulness in initial PD evaluation is unproven.

“Penile biothesiometry is a non-invasive test used to provide objective sensory information. However, the utility of this testing in the context of the initial PD evaluation is unproven.32, 33”

• cites [32] Terrier, 2018, Penile Sensory Changes After Plaque Incision and Grafting Surgery for Peyronie's Disease, J Sex Med sourcePartly supported

  The Methods describe biothesiometry as a quantitative measure of penile vibration sensation, and the Discussion calls it non-invasive. The Discussion demonstrates its use before and after plaque incision and grafting, but does not assess whether it is useful in the initial evaluation of Peyronie’s disease. The copy provides no page numbers for these passages. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [33] Twidwell, 2016, Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study, Int J Impot Res sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The CUA considers verapamil a second-line intralesional therapy along with interferon, and notes that injection protocols likely influence outcomes.

“The CUA considers verapamil to be a second line intralesional therapy (along with IFN), and notes that injection protocols (volume, frequency, concentration, treatment duration) likely influence outcomes.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Intralesional therapies section recommends intralesional verapamil, and the guideline also says intralesional interferon can be used. The discussion of verapamil states that injection volume, frequency, concentration and duration appear to affect outcomes. Our copy does not designate verapamil and interferon as second-line therapies; page numbers are unavailable in the indexed passages. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

All panels acknowledge these psychosocial concerns and stress assessing psychological burden with subjective and objective measures, including the PDQ symptom-bother domain.

“These concerns are acknowledged by all guideline panels with emphasis placed on assessing psychological burden through subjective and objective measures, including the PDQ which has a specific domain pertaining to symptom bother.1, 26, 28, 29”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The Background section on psychosocial functioning acknowledges emotional distress and relationship difficulties, and the Diagnosis guideline calls for a patient history that assesses distress alongside a physical examination. Our copy does not recommend subjective and objective measures of psychological burden or mention the PDQ symptom-bother domain. This AUA guideline also cannot establish what all guideline panels recommend. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourceSupported
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

The AUA, CUA, and EAU recommend against oral vitamin E with or without L-carnitine, tamoxifen, procarbazine, and omega-3 fatty acids because of clear lack of efficacy.

“recommend against oral therapy with vitamin E (+/− L-carnitine), tamoxifen, procarbazine, and omega-3 fatty acids due to a clear lack of efficacy.”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The AUA guideline’s Treatment section (page not supplied) recommends against all the listed oral therapies and says there is no convincing evidence of their efficacy. This source does not establish what the CUA or EAU recommend, and its wording is more cautious than a 'clear lack of efficacy.' (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Clinical principle section says the CUA does not recommend vitamin E, tamoxifen, procarbazine, or vitamin E/L-carnitine for standard Peyronie’s disease care in Canada, and specifically says vitamin E lacks evidence of efficacy. The passages do not establish the claimed recommendation by all three associations, include omega-3 fatty acids in that list, or establish a clear lack of efficacy for every listed agent. Page numbers were not available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

The CUA, EAU, and ISSM strongly recommend against synthetic grafts because of adverse outcomes including persistent or recurrent fibrosis and infection.

“The CUA, EAU, and ISSM panels recommend strongly against synthetic grafts as they have been associated with adverse outcomes including persistent/recurrent fibrosis and infection.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Grafting procedures section strongly recommends against synthetic grafts because of infection risk and graft inflammation causing tissue fibrosis. This is the CUA guideline’s recommendation; the passages do not establish that the EAU and ISSM panels make the same recommendation, or specifically describe the fibrosis as persistent or recurrent. No page number is available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

The ISSM suggests stable Peyronie's disease symptoms for at least 6 months before surgery, while the AUA indicates symptom duration of at least 12 months with 3 to 6 months of symptom stability.

“the ISSM panel suggests that patients should have stable PD symptoms for at least 6 months prior to surgery as compared to the AUA which indicates symptom duration of at least 12 months with 3–6 months of symptom stability.”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The Guideline Statements > Treatment section says surgical candidates should be assessed based on stable disease, and Patient Presentation > Active vs. Stable Disease defines stability as symptoms unchanged for at least three months. The passages found do not establish a requirement of at least 12 months’ symptom duration or a 3–6-month stability window for surgery; the cited >12-month duration concerns an interferon trial, not surgery. The ISSM recommendation is not being attributed to this AUA guideline. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

May combine two claims.

Interferon is considered second-line intralesional therapy by the CUA but is rarely used in Canada because of cost and adverse events such as sinusitis and flu-like symptoms.

“while considered second line for intralesional therapy according to the CUA guideline panel, IFN is rarely used in Canada owing to cost and potential adverse events such as sinusitis and flu-like symptoms.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The guideline’s interferon discussion says intralesional IFN is rarely used in Canada because of cost and adverse events, including sinusitis and flu-like symptoms. It says IFN can be used in selected men, but does not explicitly classify it as second-line intralesional therapy; the Intralesional therapies section instead recommends verapamil. The indexed passages provide no page numbers. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The CUA highlights penile traction therapy after plication to optimize outcomes including length, though studies of efficacy are limited.

“Interestingly, the CUA highlights the utility of PTT post-plication to optimize outcomes including length, albeit with limited studies regarding efficacy at this time.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The AUA suggests providers keep in mind the moderate average curvature reduction of 13.5 degrees compared with 9 degrees in placebo groups.

“The AUA guideline panel further suggests that the providers must keep the relatively moderate average curvature reduction of 13.5-degrees compared with 9-degree in placebo groups in mind.”

• cites [1] Nehra, 2015, Peyronie's Disease: AUA Guideline, J Urol sourcePartly supported

  The Treatment section describes a modest curvature-reduction difference, but not the comparison claimed. It reports 17° with collagenase versus 9.3° with placebo; a separate interferon trial reports 13.5° versus 4.5° with placebo. The claim combines the treatment result from one comparison with the placebo result from another (page unavailable in our copy). (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

The CUA, EAU, and ISSM suggest plaque incision with grafting be reserved for men with more severe penile deformity.

“The CUA, EAU, and ISSM guideline panels suggest that plaque incision with grafting be reserved for men with more severe penile deformity.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The CUA guideline’s Grafting procedures section recommends grafting for men with severe or complex curvature and other substantial deformities, supporting the CUA portion of the claim. The passages do not establish what the EAU or ISSM guideline panels recommend. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

The PDQ is considered an adjunctive evaluation tool by the CUA and ISSM, and the EAU recommends it during initial assessment and follow-up to determine treatment efficacy beyond objective measurements.

“The PDQ is considered an adjunctive evaluation tool by the CUA and ISSM, and the EAU now recommends this tool during the initial assessment and subsequent follow-up to determine treatment efficacy beyond simple objective measurements.”

• cites [26] Bella, 2018, Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature, Can Urol Assoc J sourcePartly supported

  The Sexual function section of the CUA guideline (page not provided) presents the PDQ as an optional assessment tool and says it can track changes in symptoms and disease progression. The copy does not establish that the ISSM endorses the PDQ or that the EAU recommends it for initial assessment and follow-up to evaluate treatment efficacy beyond objective measurements. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source
• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

All guidelines note a possible genetic predisposition to PD, and the 2020 EAU guideline lists genes linked to its pathophysiology.

“All guideline documents also highlight the potential genetic predisposition with PD, and the newest EAU guidelines from 2020 describe the various genes that have been implicated in PD pathophysiology.29”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

All four guideline panels conducted systematic literature reviews, graded recommendations when evidence allowed, and added consensus statements when evidence was absent.

“All guideline panels performed systematic literature reviews, assigned graded recommendations based on level of evidence when possible, and presented consensus statements where evidence is lacking.”

May combine two claims.

All guidelines state that during the active phase curvature worsens in about half of patients and improves in fewer than 10-15%.

“All guidelines emphasize that curvature worsens in nearly half of all patients during the active phase and improves in < 10–15% of patients.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The ISSM guideline stresses that grafting surgeries should be done by experts.

“Specifically citing the complexity of grafting surgeries, ISSM again emphasizes that these should be performed by experts.28”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

The panels agree that PD pathophysiology involves fibrosis of the tunica albuginea, probably from abnormal healing after repeated minor trauma.

“There is agreement amongst the guideline panels in characterizing the underlying pathophysiology as fibrosis of the tunica albuginea likely caused from aberrant healing incited by repetitive minor trauma.”

Classified as probably not a substantial claim.

Penile ultrasound with or without Doppler is an adjunctive test for characterizing plaque and penile hemodynamics.

“Penile ultrasound (PU) with or without Doppler (PDDU) is an adjunctive test used to characterize penile plaque and penile hemodynamics.”

May combine two claims.

All four guidelines cover PD epidemiology, pathophysiology, and risk factors and give recommendations for evaluation and management.

“All guidelines provide a review of PD epidemiology, pathophysiology, and associated risk factors in addition to recommendations regarding evaluation and management options.”

May combine two claims.

All guidelines stress defining the degree of deformity and ED, although they emphasize different parts of history taking.

“Each guideline highlights slightly disparate aspects of history taking, but all emphasize the importance of defining the degree of deformity and ED.”

Classified as probably not a substantial claim. May combine two claims.

The updated EAU guideline stresses in-office ICI because it is superior to other assessment methods, though this is based on expert opinion and a weak recommendation.

“The new EAU penile curvature guideline emphasizes the importance of evaluation with in-office ICI due to superiority over alternative methods of assessment, albeit based on expert opinion and with a “weak” data recommendation.29”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

IIEF and PDQ are discussed for their possible usefulness in measuring symptom severity and treatment outcomes.

“Both the international index of erectile function (IIEF) and Peyronie’s Disease Questionnaire (PDQ) are discussed based on their potential utility for defining symptom severity and treatment-related outcomes.17, 21”

• cites [17] Coyne, 2015, Responsiveness of the Peyronie's Disease Questionnaire (PDQ), J Sex Med sourceNot checked — no full text of the source
• cites [21] Ziegelmann, 2020, Peyronie's Disease Intervention Studies: An Exploration of Modern-Era Challenges in Study Design and Evaluating Treatment Outcomes, J Sex Med sourceNot checked — no full text of the source

May combine two claims.

Evidence for the PD workup is notably limited, so recommendations rely largely on clinical consensus.

“There is a notable lack of evidence regarding the workup for PD, and therefore recommendations are largely based on clinical consensus.”

May combine two claims.

No guideline requires routine use of these questionnaires, but ISSM specifically emphasizes PDQ for baseline data and monitoring treatment outcomes.

“No guideline mandates the routine use of these questionnaires, although the ISSM guideline panel explicitly emphasizes the PDQ to establish baseline data and monitor treatment outcomes.28”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

May combine two claims.

There is no firmly agreed timeframe for the active phase, and guidelines both agree and disagree on how stable-phase PD is defined.

“There is no firmly agreed-upon timeframe that constitutes the active phase of PD, and there is both agreement and discrepancy amongst the guidelines pertaining to the definition of stable-phase PD.”

Classified as probably not a substantial claim. May combine two claims.

EAU recommends PDDU only for ED evaluation and advises against PU for plaque characterization because evidence is weak.

“PDDU is recommended by EAU guidelines only for the evaluation of ED, and the panel explicitly recommends against PU to characterize the penile plaque based on the weak level of evidence to support any change in diagnosis or treatment outcomes.29”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

All guidelines note that PD is linked to worse quality of life and psychological health, with many patients experiencing depression.

“All guidelines also highlight the association of PD with decreased quality of life and psychological health with a significant number of patients experiencing depression.”

Probably not a substantial claim: may not pass S3 (load-bearing).

If treatment is desired, especially invasive treatment, further evaluation is recommended.

“If treatment is desired, particularly invasive-treatments, further evaluation is recommended.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The guidelines describe PD in similar terms: an acquired penile condition with pain, deformity, erectile dysfunction, and distress.

“PD is similarly described across all guidelines as an acquired penile abnormality associated with pain, deformity, erectile dysfunction (ED), and distress.”

• AssumptionRests on an assumption: Recommendations from the different guidelines can be meaningfully compared despite their different grading systems and terminology.

Probably not a substantial claim: may not pass S3 (load-bearing).

The treating physician must tell patients about risks, benefits, and treatment alternatives at the initial and later consultations.

“The treating physician must inform patients on potential risks, benefits, and treatment alternatives during the initial consultation and subsequent interactions.”

May combine two claims.

There is general agreement that extracorporeal shockwave therapy may be offered for pain but not for curvature correction.

“There is general agreement that extracorporeal shockwave therapy (ESWT) may be offered for pain, but not curvature correction.”

Classified as probably not a substantial claim.

Because PD is benign, observation alone is appropriate when the patient is adequately informed.

“and given the benign nature observation alone is an appropriate treatment decision when made by the adequately informed patient.”

• AssumptionRests on an assumption: PD is benign.

Probably not a substantial claim: may not pass S3 (load-bearing).

The EAU recommendation for penile traction therapy or vacuum erection devices is considered weak because of lack of robust data.

“However, this recommendation is considered “weak” due to the lack of robust data to date.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The ISSM underscores lack of proven benefit for iontophoresis and suggests that curvature decrease in some series may be due to energy delivered to tissue.

“the ISSM guideline panel underscores the lack of proven benefit and suggests that the decrease in curvature seen in some series may be due to the energy delivered to the tissue.”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The ISSM does not recommend any oral therapy as primary treatment for Peyronie's disease because of lack of proven benefit in rigorous clinical studies.

“The ISSM guideline does not recommend any oral therapy as primary treatment due to the lack of proven benefit in rigorous clinical studies to date.”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Radiation is not recommended by the AUA and CUA because potential risks outweigh proven benefits.

“Radiation is not recommended by the AUA and CUA guidelines given potential associated risks which outweigh any proven benefits.”

May combine two claims.

The CUA and EAU specifically recommend against corticosteroids, while the AUA and ISSM make no specific recommendation but cite significant limitations in the literature.

“Corticosteroids are specifically recommended against by the CUA and EAU panels, whereas the AUA and ISSM guidelines do not make specific recommendations but cite significant limitations in the available literature.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The EAU states that penile traction therapy or vacuum erection devices may be used as monotherapy or in combination to reduce penile deformity.

“The EAU guideline states that penile traction therapy (PTT) or vacuum erection devices may be used as monotherapy or in combination with other treatments to reduce penile deformity.”

• cites {Salonia A., 2020 #22}Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

The EAU recommends against POTABA, pentoxifylline, and colchicine for Peyronie's disease.

“The EAU panel recommends against potassium para-aminobenzoate (POTABA), pentoxifylline, and colchicine”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

AUA and ISSM discuss biothesiometry for selected patients with reduced penile sensation, and it may provide baseline sensation for pre- and post-treatment comparison.

“The AUA and ISSM guideline panels discuss the potential utility of biothesiometry in select patients who report diminished penile sensation. This testing may also establish baseline objective penile sensation with which to compare pre- and post-treatment.33”

• cites [33] Twidwell, 2016, Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study, Int J Impot Res sourceNot checked — no full text of the source

May combine two claims.

Collagenase clostridium histolyticum received national regulatory approval in the USA and was available until recently in Canada and the European Union, but is no longer available in Canada or the European Union.

“The latter has received national regulatory approval in the USA and was also available, until recently, in Canada and the European Union (currently CCH is no longer available in Canada or the European Union).”

• cites [35] Levine, 2002, Experience with intraplaque injection of verapamil for Peyronie's disease, J UrolNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The panels say clinicians should consider referring patients to a mental health professional when significant bother is found.

“panels state that clinicians should consider placing a referral for consultation with a mental health professional if significant bother is identified.”

The quote only partly states this claim.

The AUA and CUA consider POTABA, pentoxifylline, colchicine, and co-enzyme Q10 as potential options as monotherapy or in combination, while acknowledging insufficient evidence.

“whereas the AUA and CUA guideline panels consider these agents as potential options, along with co-enzyme Q10, when used as monotherapy or in combination with other treatment modalities”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Surgical treatment for Peyronie's disease includes penile plication, plaque incision or partial excision and grafting, and penile prosthesis placement with concurrent straightening maneuvers as indicated.

“Surgical treatment for PD includes penile plication, plaque incision or partial excision and grafting, and penile prosthesis placement with concurrent straightening maneuvers as indicated.”

Classified as probably not a substantial claim. May combine two claims.

Surgery is favored when conservative management fails, deformity is significant enough to preclude intercourse, or the patient prefers surgery.

“Surgery is favored with failure of conservative management, significant deformity precluding intercourse, or patient preference.”

May combine two claims.

Intralesional collagenase clostridium histolyticum is supported by all guidelines based on robust data from two separate double-blind randomized placebo-controlled trials published in 2013.

“Intralesional CCH is supported by all guidelines based on robust data from two-separate double-blind, randomized, placebo-controlled trials originally published in 2013.”

• cites [19] Gelbard, 2013, Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies, J Urol sourceNot checked — no full text of the source

May combine two claims.

All four guidelines support intralesional interferon because of potential modest benefits in published literature, including a multi-center randomized placebo-controlled trial by Hellstrom et al. in 2006.

“All four guidelines support intralesional IFN due to the potential modest benefits seen in the published literature including results from a multi-center, randomized, placebo-controlled trial by Hellstrom et al. in 2006.”

• cites [38] Gelbard, 2015, Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach, J Sex Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

For residual curvature greater than 30 degrees after prosthesis placement, manual modeling is recommended as first-line treatment.

“For residual curvature > 30 degrees after prosthesis placement, manual modeling is recommended as first line.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

History and physical examination are mandatory and can be used to diagnose Peyronie's disease.

“History and physical examination is mandatory and can be used to diagnose PD.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The EAU states a de-gloving incision is standard, but other modifications such as a ventral incision have been described.

“The EAU states that a de-gloving incision is considered standard, but other modifications such as a ventral incision have been described.”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

There are inherent challenges in evaluating and treating men with Peyronie's disease.

“There are inherent challenges pertaining to the evaluation and treatment of men with PD.”

• cites [21] Ziegelmann, 2020, Peyronie's Disease Intervention Studies: An Exploration of Modern-Era Challenges in Study Design and Evaluating Treatment Outcomes, J Sex Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

The aim of surgery for Peyronie's disease is to correct penile curvature rather than pain.

“The aim is to correct penile curvature rather than pain.”

May combine two claims.

Specific recommendations for collagenase clostridium histolyticum in acute phase, ventral curvature, hourglass deformity with hinge-effect, and protocol modifications are lacking because of absence of robust evidence, but no published guideline overtly recommends against them.

“Specific recommendations regarding CCH in the acute phase, ventral curvature, hourglass deformity with hinge-effect, and protocol modifications are lacking due to the absence of robust supportive evidence, but are not overtly recommended against in any published PD guideline.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The EAU emphasizes non-absorbable or slowly absorbable sutures should be used to minimize curvature recurrence during plication.

“They also emphasize that non-absorbable or slowly absorbable sutures should be used to minimize the risk for curvature recurrence during plication procedures.”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

If curvature remains greater than 30 degrees after modeling, penile plication or plaque releasing incision with or without grafting or coverage can be used.

“If the curve remains >30 degrees after modeling, penile plication or plaque releasing incisión with/without grafting/coverage can be employed.”

May combine two claims.

The EAU makes similar recommendations for collagenase clostridium histolyticum but states curvature should be dorsal or lateral.

“The EAU makes similar recommendations, but states that curvature should be dorsal or lateral.”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The EAU says sliding techniques or other length-restoration approaches to increase penile length should be used with caution because of serious side effects and offered only by highly experienced surgeons.

“Sliding techniques or other “length-restoration” approaches to increase penile length are to be used with caution per the EAU, given the risk of serious side effects, and should be offered only by highly experienced surgeons.”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The ISSM recommends grafting over the defect if a defect greater than 2 cm results.

“Per the ISSM guideline, grafting over the defect is recommended if a defect >2 cm results.”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source
• cites [44] Levine, 2010, Inflatable penile prosthesis placement in men with Peyronie's disease and drug-resistant erectile dysfunction: A single-center study, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The four clinical guidelines reviewed provide a summary of available evidence with the goal of providing a framework for treatment plans for Peyronie's disease patients.

“the four separate clinical guidelines reviewed herein provide readers with a summary of the available evidence, with the goal of providing a framework upon which to build treatment plans for patients suffering from PD.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Intracavernosal injection is the gold standard for evaluating penile deformity, particularly before invasive intervention.

“Intracavernosal injection is the gold standard to evaluate penile deformity, particularly prior to invasive intervention.”

May combine two claims.

There is consensus among panels that inflatable penile prosthesis models are generally preferred, although the EAU cites similar satisfaction rates with malleable models.

“There seems to be consensus amongst the panels that inflatable penile prosthesis models are generally preferred, although the EAU guideline cites similar satisfaction rates with malleable prosthesis models as well.”

• cites [29] Salonia, 2020Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The ISSM highlights traction combined with PDE5 inhibitors as an option for penile rehabilitation.

“ISSM also highlights traction in combination with PDE-5i as an option for penile rehabilitation.”

• cites [28] Chung, 2016, Evidence-Based Management Guidelines on Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Specific guideline recommendations on surgical approach are vague, giving surgeons leeway to choose the approach they feel is optimal.

“Specific guideline recommendations pertaining to surgical approach are left somewhat vague, providing leeway for the surgeon to offer whatever approach she/he feels is optimal.”

Probably not a substantial claim: may not pass S4 (based).

Four different clinical guidelines have been published to streamline evaluation and management of Peyronie's disease.

“Four different clinical guidelines have been published to streamline the evaluation and management of PD.”

May combine two claims.

Patient recall and photography are more convenient than objective curvature assessment but lack objective information on penile girth deformities and erection firmness.

“Patient recall and photography (home or in-office photographs) are more convenient than performing an objective curvature assessment, but they lack objective information on penile girth deformities and erection firmness.”

• cites [46] Ohebshalom, 2007, Measurement of penile curvature in Peyronie's disease patients: comparison of three methods, J Sex Med sourceNot checked — no full text of the source
• cites [47] Nascimento, 2018, Impact of Camera Deviation on Penile Curvature Assessment Using 2D Pictures, J Sex Med sourceNot checked — no full text of the source
• cites [48] Margolin, 2017, Three-Dimensional Photography for Quantitative Assessment of Penile Volume-Loss Deformities in Peyronie's Disease, J Sex Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Plication and incision or grafting surgery is reserved for patients with preserved erectile function, while penile prosthesis implantation is the optimal surgical option for Peyronie's disease patients with erectile dysfunction unresponsive to pharmacotherapy or vacuum erection devices.

“Plication and incision and/or grafting surgery is reserved for patients with preserved erectile function, whereas penile prosthesis implantation is the optimal surgical option for PD patients with erectile dysfunction unresponsive to pharmacotherapy and/or VED.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Intralesional injections may be offered to patients who desire non-surgical treatment.

“Intralesional injections may be offered to patients who desire non-surgical treatment.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Extracorporeal shockwave therapy can treat penile pain associated with Peyronie's disease but should not be used for deformity such as curvature or plaque size.

“Extracorporeal shock wave therapy can be used to treat penile pain associated with PD, but should not be used to address penile deformity such as curvature or plaque size.”

Probably not a substantial claim: may not pass S4 (based).

Penile prosthesis is the best surgical option for Peyronie's disease patients with medication-refractory erectile dysfunction.

“penile prosthesis is the best surgical option for patients with medication refractory ED.”

Probably not a substantial claim: may not pass S4 (based).

Surgery should only be offered to patients in the stable or chronic phase of Peyronie's disease.

“Surgery should only be offered to patients who are in the stable or chronic phase of PD.”

Classified as probably not a substantial claim. May combine two claims.

Generally agreed principles for clinical evaluation include appropriate clinician expertise, thorough history and physical examination, and objective curvature assessment before invasive therapy.

“Generally agreed upon principles for the clinical evaluation include appropriate clinician expertise, a thorough history and physical examination, and use of objective curvature assessment prior to invasive therapy.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Peyronie's disease carries a significant psychological burden for most patients and their partners.

“As noted by all of the guideline panels, PD carries a significant psychological burden for the majority of patients and even their partners.”

Probably not a substantial claim: may not pass S4 (based).

Consensus supports that oral medications for Peyronie's disease are generally efficacious.

“consensus supports that oral medications are generally efficacious”

Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

Careful counseling with shared decision making is required at treatment onset, and patients should be aware of limitations in available treatment data.

“Careful counseling with shared decisión making is required at the onset of treatment, and patients should be aware of limitations with the available data pertaining to treatment options.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Other questionnaires such as the IIEF and erection harness scale provide objective information on erectile function but have not been validated in the Peyronie's disease population.

“Other questionnaires such as the IIEF and the erection harness scale provide objective information on erectile function, but have not been validated in the PD population.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Before the PDQ, there were very few objective tools to assess the psychosocial impact of Peyronie's disease symptoms and treatments.

“Prior to the development of the PDQ, we had very few objective tools with which to assess the psychosocial impact of PD symptoms and treatments.”

Classified as probably not a substantial claim.

Consensus supports that surgery should be reserved for patients in the stable phase of Peyronie's disease, although the definition of stable varies.

“surgery should be reserved for patients in the stable phase of disease (although this definition somewhat varies).”

Classified as probably not a substantial claim.

Consensus supports that intralesional injections are an appropriate noninvasive treatment option.

“intralesional injections are an appropriate noninvasive treatment option”

May combine two claims.

Because the PD evidence base is limited, guideline panels often cannot make definitive evidence-based recommendations and instead use expert opinion.

“Limitations with the PD literature preclude definitive evidence-based recommendations in many instances, and the panels often rely on expert opinion to supplement their guideline statements.”

May combine two claims.

This reliance on expert opinion produces variation between guideline recommendations and leaves clinicians uncertain.

“This creates the opportunity for heterogeneity amongst the various guideline recommendations, and lends to ongoing uncertainty for many clinicians who encounter PD in clinical practice.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Intralesional verapamil is a calcium-channel blocker proposed to modulate extracellular matrix proteins and produce beneficial therapeutic effects in men with Peyronie's disease.

“Intralesional verapamil is a calcium-channel blocker that is proposed to modulate extraceullar matrix proteins resulting in beneficial therapeutic effects in men with PD.”

• cites [36] Duncan, 1991, Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma, Scand J Urol Nephrol sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

The lack of consensus on stability duration underscores heterogeneity in urology patient populations and supports the need for a standardized definition for consistent results reporting in future intervention studies.

“This lack of consensus underscores the heterogeneity in patient populations that is routinely seen within the urology literature, and supports the need for a more standardized definition to ensure consistent results reporting with subsequent intervention studies.”